Translating this to clinical trial, Multhoff et al. showed that four cycles of adoptive transfer of autologous NK cells pre-stimulated with TKD and IL-2 was well-tolerated and resulted in increase in the number of NK cells in peripheral blood of patients with mHSP70-positive non-small cell lung cancer (NSCLC) following radiochemotherapy in phase II clinical trial (140). This evidence concerns the gene IL2 and non-small cell lung carcinoma.